With new name, new CEO, Cas­ca­di­an now rolls out a new piv­otal plan for lead can­cer drug

Cas­ca­di­an $CASC changed its name (from On­cothyre­on) and in­stalled a new CEO in the hope of shed­ding the seem­ing curse that dogged al­most every step at the biotech. And now it has a new, ac­cel­er­at­ed de­vel­op­ment pro­gram in place for its lead drug that puts it square­ly in the piv­otal phase.

The drug tu­ca­tinib — for­mer­ly known as ONT-380 in the pre-makeover days — is a HER2 in­hibitor that has been matched up with Her­ceptin and Xelo­da in com­bat­ting treat­ment-re­sis­tant breast can­cer. It’s a pill, in­tend­ed to get through the blood-brain bar­ri­er to help some des­per­ate­ly ill pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER